Table Head | Value |
| ||
base-case | sensitivity analysis |
| ||
Cost for CTZ group, including neoadjuvant chemotherapy and surgery (USD) | 8153.7 | +25% | 10,192.1 | 8122.1 |
| −25% | 6115.3 | 4215.8 | |
Utility value of stable state | 0.89 | +11% | 1 | 4710.2 |
| −20% | 0.7 | 13265.1 | |
Duration of progression and hormonal chemotherapy state (months) | 18 | +6 | 24 | 6049.7 |
| −6 | 12 | 6265.5 | |
Cost of progression and chemotherapy state (USD) |
| +25% | 1841.3 | 5856.2 |
| −25% | 1104.8 | 6481.8 |